title: Optimizing ICD programming for shock reduction.
abstract: With the increasing numbers of patients with implantable cardioverter/defibrillators for primary prevention (PP), the topic of inappropriate therapy becomes more and more important. If a shock intervention, e.g. for rapidly conducted atrial fibrillation or fast VT (FVT), represents the first reminder of the implantable cardioverter/defibrillator (ICD), the adherence to the therapy will decrease. Moreover, anxiety to receive the next inappropriate ICD Rx is able to initiate a bad quality of life or depression. Starting with the PainFREE Rx II Trial results, the programming of antitachycardia pacing was able to terminate even fast ventricular arrhythmia, i.e. ≥ 188 bpm, in three of four episodes. Thereafter, several studies evaluated whether a prolongation in ventricular tachyarrhythmia (VT) detection is able to reduce unnecessary ICD Rx owing to nonsustained VT. The PREPARE trial evaluated this concept in a cohort of PP patients. This nonrandomized study compared a historical control group to patients with a prolonged detection interval. The results underline the idea that an extension in detection time leads to a significant decrease in ICD Rx for supra- as well as VT. The RELEVANT study investigated in a randomized fashion the outcome of an increase in detection time in nonischemic patients under CRT including an ICD. The findings clearly demonstrated a reduction in ICD Rx as well as hospital admissions, significantly. Currently, the ADVANCE III trial investigates a 30/40 interval detection compared to 18/24 for FVT in prospective randomized fashion in patients for primary or secondary prevention including all ICD devices.
authors.affiliation: Department of Medicine-Cardiology, University of Bonn, Sigmund-Freud, Str. 25, 53105 Bonn, Germany. joerg.schwab@ukb.uni-bonn.de
authors.forename: Joerg O
authors.initials: JO
authors.lastname: Schwab
mesh_terms: D001281:Atrial Fibrillation / Q000628:therapy*; D002986:Clinical Trials as Topic; D017147:Defibrillators, Implantable / Q000009:adverse effects; D006801:Humans; D017180:Tachycardia, Ventricular / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome